HIMS · Hims & Hers Health, Inc. · Investor Relations

The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. “True health doesn’t happen in a vacuum. It’s the result of the data you gather, the insights you can access, and the daily choices you make,” said Dheerja Kaur, Chief Product Officer at Hims & Hers. “By leveraging our scale, we’re bringing health and wellness innovations like Prenuvo’s whole body MRI scans and Eight Sleep’s

Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims & Hers will become the largest global consumer health platform for access to more affordable, approved medications. The US weight loss landscape has transformed dramatically since Hims & Hers entered the market in 2023. Progress in the industry has made a broader range of FDA-approved GLP-1 treatments

Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. “More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leader in consumer health,” said Andrew Dudum, co-founder and CEO. “In 2025, we made it possible for more customers across the world to depend on us